Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Dose Linearity of Budesonide in Japanese and Non-Asian Healthy Adults
jRCT2071240012Completed
- Sponsor
- Viatris
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of budesonide in IgA nephropathy (IgAN) (2 arms), sponsored by Viatris. Primary endpoints: Relative bioavailability of budesonide and Dose linearity of budesonide. Started May 2024; status: completed.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2071240012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240012.